A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) Who Have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event - ACCLAIM-Lp(a)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) Who Have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event - ACCLAIM-Lp(a)
The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke. The study drug will be administered subcutaneously (SC) (under the skin). Approximately 1700 additional participants will be enrolled in an addendum to explore Lp(a) lowering with an alternative dosing schema.
Inclusion Criteria:
Have Lipoprotein(a) [Lp(a)] ≥175 nanomoles per liter (nmol/L).
Meet criteria of either 2a or 2b:
2a: Individuals 18 years of age or older with established atherosclerotic cardiovascular disease (ASCVD) with an event or revascularization.
2b: Individuals 55 years of age or older who are at risk for a first cardiovascular (CV) event and either: Documented coronary artery disease (CAD), carotid stenosis, or peripheral artery disease (PAD) without history of event or revascularization; known familial hypercholesteremia; or a combination of high-risk factors.
Exclusion Criteria:
Have had a major cardiovascular event or surgery, such as myocardial infarction (MI), stroke or coronary or peripheral revascularization, < 60 days before screening
Have uncontrolled hypertension
Have New York Heart Association class IV heart failure.
Have lipoprotein apheresis within 90 days of screening, or planned lipoprotein apheresis during the study.
Have severe renal failure, defined as
Have a diagnosis of active nephrotic syndrome, or urine albumin-creatinine ratio (UACR) of ≥5000 mg/g at screening Visit 1.
Have acute or chronic hepatitis, known cirrhosis, signs and symptoms of any other liver disease other than metabolic-associated steatotic liver disease, or exclusionary laboratory results as determined by the central laboratory during screening.
Gilbert, Arizona 85296, United States
Sun City West, Arizona 85375, United States
La Jolla, California 92037-7410, United States
Los Angeles, California 90210, United States
Toluca Lake, California 91602, United States
Torrance, California 90502, United States
Clearwater, Florida 33756, United States
Fort Lauderdale, Florida 33312, United States
Largo, Florida 33777, United States
Safety Harbor, Florida 34695, United States
Wellington, Florida 33449, United States
Springfield, Illinois 62711, United States
Hyattsville, Maryland 20782, United States
Troy, Michigan 48098, United States
Philadelphia, Pennsylvania 19104, United States
Houston, Texas 77030, United States
CABA, C1060ABN, Argentina
Ciudad de Buenos Aires, C1012AAR, Argentina
Rosario, 2000, Argentina
São José do Rio Preto, 15090000, Brazil
North York, M6B 3H7, Canada
Nanjing, 210000, China
Xi'an, 710038, China
Bad Friedrichshall, 74177, Germany
Dresden, 01277, Germany
Remscheid, 42859, Germany
Saint Ingbert, 66386, Germany
Kamakura-shi, 247-0056, Japan
Meguro-ku, 152-8902, Japan
Naka-gun, 259-0114, Japan
Ootaku, 143-0015, Japan
Osaka, 540-0006, Japan
Shinjuku-ku, 160-0008, Japan
Shinjyuku-ku, 162-8655, Japan
Suita-shi, 565-0853, Japan
Sunto-gun, 411-8611, Japan
Toshimaku, 171-0014, Japan
Culiacán, 80230, Mexico
Mexico City, 11650, Mexico
Chrzanów, 32-500, Poland
Nowa Sól, 67-100, Poland
Tarnów, 33-100, Poland
Dongjak-gu, 07061, South Korea
Namdong-gu, 21565, South Korea
Sosa-gu, 14754, South Korea
El Palmar, Murcia, 30120, Spain
Salamanca, 37007, Spain
Changhua County, 50006, Taiwan
Kaohsiung Niao Sung Dist, 83301, Taiwan
Tyne and Wear, SR4 7TP, United Kingdom